Demand finds MedImmune under-stocked

MedImmune Inc. (MEDI) will miss out on some $9 million in sales this quarter due to a manufacturing shortfall of its RespiGam (Respiratory Syncytial Virus Immune Globulin) product. MEDI is confident that the shortfall will be rectified by the fall, but that's a few months too late to capture more RespiGam sales during the 1996-97 RSV season

RSV in children is a seasonal disorder, typically running October through March. MEDI sold $13.9 million of the product in the fourth quarter. Because of the shortfall, the company is likely to sell only $5 million worth of the product in the first quarter. A full course of RespiGam therapy costs $5,000...